Physician profile

Michael Mccartney

Family Medicine · Gastonia, NC

NPI 1164541637

$3,472.37

in general payments reported to CMS, 2019-2025

45 companies · $862 in 2025

The $862 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,198.90

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $388.37 2020-2025
Novo Nordisk INC $385.84 2019-2025 Wegovy, Ozempic, Rybelsus
Lilly USA, LLC $378.55 2019-2025 Jardiance, Mounjaro, Zepbound
Astrazeneca Pharmaceuticals Lp $217.24 2019-2025 Farxiga, Breztri, Airsupra
Pfizer INC. $190.02 2020-2025
Glaxosmithkline, LLC. $181.70 2020-2025 Shingrix, Arexvy, Trelegy Ellipta
Amgen INC. $171.48 2020-2025 Otezla, Repatha, Repatha
Djo, LLC $126.36 2024 Chattanooga, Procare
Astellas Pharma US INC $103.55 2020-2023 Veozah, Myrbetriq
Merck Sharp & Dohme LLC $97.94 2020-2025 Verquvo, Capvaxive, Vaxneuvance
Exact Sciences Corporation $85.04 2023-2025 Cologuard Collection Kit, The Cologuard Plus Collection Kit
Boston Scientific Corporation $84.29 2022-2025 Ams 700
Janssen Pharmaceuticals, INC $66.75 2020-2024 Xarelto
Amarin Pharma, INC. $50.10 2020-2021
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $49.40 2020-2021
Show all 45 companies
CompanyGeneral paymentsYearsTop products
Tris Pharma INC $47.94 2025 Dyanavel Xr
Sanofi-Aventis U.S. LLC $47.83 2020-2021
Takeda Pharmaceuticals U.S.A., INC. $47.58 2020-2022
Dexcom, INC. $47.15 2023-2025 Dexcom G6 Transmitter
Shield Therapeutics INC $44.49 2023 Accrufer
Boehringer Ingelheim Pharmaceuticals, INC. $42.86 2021-2024 Synjardy, Jardiance
Kowa Pharmaceuticals America, INC. $41.11 2021-2024 Zoryve
Abbott Laboratories $40.14 2022-2023 Freestyle Libre 3
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $37.10 2025 Caplyta
Eisai INC. $34.09 2020-2021
Neos Therapeutics, Lp $33.59 2022-2023 Adzenys Xr-Odt
Phathom Pharmaceuticals, INC. $31.79 2024-2025 Voquezna
Novartis Pharmaceuticals Corporation $30.65 2022-2023
Bayer Healthcare Pharmaceuticals INC. $29.35 2023-2024
E.R. Squibb & Sons, L.L.C. $29.25 2022-2023 Eliquis
Sunovion Pharmaceuticals INC. $27.29 2022
Vanda Pharmaceuticals INC. $26.07 2025 Fanapt
Ars Pharmaceuticals Operations, INC. $25.48 2025 Neffy
Axsome Therapeutics, INC. $23.05 2025 Auvelity
Neurocrine Biosciences, INC. $22.74 2025
Biohaven Pharmaceutical Holding Company Ltd. $22.69 2022
Biohaven Pharmaceuticals, INC. $20.97 2021
Seqirus USA INC $20.75 2025 Fluad, Flucelvax
Esperion Therapeutics, INC. $20.00 2020
Collegium Pharmaceutical, INC. $19.62 2025 Jornay Pm
Hikma Pharmaceuticals USA $19.14 2021
Dynavax Technologies Corporation $17.66 2023 Heplisav-B
Clarus Therapeutics INC. $17.38 2021
Ibsa Pharma INC. $16.56 2020
Allergan, INC. $11.42 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael Mccartney

$3,472.37

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbvie INC.
Context
The $862 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).

https://glasscript.com/doctor/880146/michael-mccartney

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.